Insider Selling: Edwards Lifesciences (NYSE:EW) VP Sells 9,968 Shares of Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Donald Bobo, Jr. sold 9,968 shares of the business’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $82.07, for a total transaction of $818,073.76. Following the sale, the vice president owned 22,798 shares of the company’s stock, valued at approximately $1,871,031.86. This represents a 30.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded up $1.01 during midday trading on Monday, hitting $82.39. The company had a trading volume of 4,179,984 shares, compared to its average volume of 4,798,783. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The company has a market cap of $47.44 billion, a price-to-earnings ratio of 43.82, a PEG ratio of 2.04 and a beta of 0.87. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $87.89. The company has a fifty day moving average of $81.50 and a two-hundred day moving average of $82.87.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. The firm had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.Edwards Lifesciences’s revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Level Four Advisory Services LLC boosted its holdings in Edwards Lifesciences by 3.7% in the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock worth $257,000 after buying an additional 119 shares during the period. Colonial Trust Co SC boosted its holdings in Edwards Lifesciences by 0.4% in the 3rd quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock worth $2,504,000 after buying an additional 120 shares during the period. Evermay Wealth Management LLC boosted its holdings in Edwards Lifesciences by 4.0% in the 4th quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company’s stock worth $282,000 after buying an additional 128 shares during the period. Rehmann Capital Advisory Group boosted its holdings in Edwards Lifesciences by 2.1% in the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock worth $546,000 after buying an additional 130 shares during the period. Finally, Howard Capital Management Inc. boosted its holdings in Edwards Lifesciences by 3.3% in the 3rd quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock worth $322,000 after buying an additional 132 shares during the period. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective for the company in a research note on Wednesday, April 1st. Robert W. Baird upped their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. UBS Group restated a “neutral” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $95.65.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.